ExpreS2ion Biotech Holding AB (publ)
Research ExpreS2ion Biotech Holding AB (publ) (5JD0) on Bullrun: market cap EUR 998.21K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker5JD0
- ExchangeF
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 998.21K
- Financial periodQ1 2026
- RevenueSEK 1.04M
- Net income-SEK 9.59M
- Free cash flow-SEK 25.49M
- Gross margin-1.3%
Valuation Snapshot
latest market cap is EUR 998.21K.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 3.66M | -SEK 38.09M | -SEK 40.90M | 3.7% | -13.66 | SEK 47.56M | SEK 501.00K | SEK 35.69M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 998.21K | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About ExpreS2ion Biotech Holding AB (publ)
ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. The company's lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vaccines for Nipah virus, Malaria, and influenza.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ExpreS2ion Biotech Holding AB (publ)'s market cap?
ExpreS2ion Biotech Holding AB (publ)'s market capitalization is EUR 998.21K.
What does ExpreS2ion Biotech Holding AB (publ) do?
ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. The company's lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vaccines for Nipah virus, Malaria, and influenza. It also offers GlycoX-S2, a glyco-engineered variants of the ExpreS2 platform to modify glycosylation patterns in expressed proteins.